Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Tablets Under Fasted Conditions

The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fasted conditions.

Inclusion Criteria:

• No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

• Positive test for HIV, Hepatitis B, or Hepatitis C.
• Treatment with known enzyme altering drugs.
• History of allergic or adverse response to naratriptan hydrochloride or any comparable or similar product.